However, treatment with neurotrophic compounds has previously been demonstrated to attenuate neurodegenerative disease pathology in a triple-transgenic Alzheimer’s disease mouse model harboring human APPswe, PS1, and tau mutations93,94. The gene discussed is PSEN1; the disease is early-onset autosomal dominant Alzheimer disease.